Bio

Academic Appointments


  • Clinical Assistant Professor, Pediatrics

Administrative Appointments


  • Associate Clerkship Director, Pediatrics, Stanford School of Medicine (2019 - Present)
  • Faculty Coach, Pediatrics, Stanford Pediatrics Residency Program (2019 - Present)
  • Associate Course Director, Early Clinical Experiences, Stanford School of Medicine (2018 - Present)
  • Educators-4-CARE Associate, Stanford School of Medicine (2017 - Present)
  • Co-Director, Silver Team Pediatrics Resident Rotation, Stanford School of Medicine, Department of Pediatrics (2018 - Present)

Honors & Awards


  • Inpatient Fellow of the Year Teaching Award, Stanford Pediatrics Residency Program (2018)
  • Alpha Omega Alpha Honors Medical Society, Stanford School of Medicine (2017)
  • Honors Certificate in Medical Education, Clinical Teaching Seminar Series Program, Stanford School of Medicine Teaching and Mentoring Academy (2017)
  • Letter of Teaching Distinction in Pediatric Medical Student Clerkship, Stanford School of Medicine (2015, 2018)
  • Honor Roll for Teaching in Pediatric Medical Student Clerkship, Stanford School of Medicine (2015, 2017, 2018)
  • Gold Humanism and Excellence in Teaching, Stanford School of Medicine (2015)
  • Medical Student, Gold Humanism Honor Society, Stanford School of Medicine (2013)

Professional Education


  • Board Certification, American Board of Pediatrics, Pediatrics (2017)
  • Fellowship, Stanford School of Medicine, Pediatric Hospital Medicine (2019)
  • Residency, Stanford University School of Medicine, Pediatrics (2017)
  • Internship, Stanford University School of Medicine, Pediatrics (2015)
  • MD, Stanford University School of Medicine (2014)
  • BA, Harvard College, Molecular and Cellular Biology (2010)

Research & Scholarship

Current Research and Scholarly Interests


Medical Student Education, Patient Education, High Value Care

Teaching

2019-20 Courses


Publications

All Publications


  • Provision of Transition Education and Referral Patterns from Pediatric Cardiology to Adult Cardiac Care. Pediatric cardiology Harbison, A. L., Grady, S., Chi, K., Fernandes, S. M. 2016; 37 (2): 232-238

    Abstract

    ACC/AHA guidelines recommend a structured preparation for and transfer to adult-oriented cardiac care for adult survivors of pediatric onset heart disease (POHD). Given this, we sought to describe the transition and transfer practices for a cohort of young adults with POHD and to determine factors associated with successful transfer to adult-oriented cardiac care. We performed a single-center, retrospective chart review on patients ≥18 years of age, with POHD likely to require lifelong cardiac care, who were seen in outpatient pediatric cardiology (PC) between 2008 and 2011. Successful transfer was defined as the subsequent attendance at adult cardiology (AC) within 2 years of PC visit. We identified 118 patients who met study criteria. Mean age 22.4 ± 2.0 years, 59 % male, 64 % white and 40 % Hispanic. Mean transition education topics noted was 3.3 ± 1.8 out of 20 and covered the underlying cardiac disease (89 %), follow-up and current medications (56 %) and exercise limitations (34 %). Recommendations for follow-up were AC (57 %) and PC (33 %). Of those told to transfer to AC, 79 % successfully transferred. Characteristics of successful transfer included: prior cardiac surgery (p = 0.008), cardiac medication use (p = 0.006) and frequency of follow-up ≤1 year (p = 0.037). One-quarter of all subjects did not follow-up within at least 2 years. Despite published guidelines, transition education appears lacking and the approach to transfer to adult cardiac care is not consistent. Given the increased risk of morbidity and mortality in this patient population, standardization of transition education and transfer processes appear warranted.

    View details for DOI 10.1007/s00246-015-1267-5

    View details for PubMedID 26385471

  • Progressing Toward a Cohesive Pediatric F-18-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary? JOURNAL OF NUCLEAR MEDICINE Klenk, C., Gawande, R., Vy Thao Tran, V. T., Leung, J. T., Chi, K., Owen, D., Luna-Fineman, S., Sakamoto, K. M., McMillan, A., Quon, A., Daldrup-Link, H. E. 2016; 57 (1): 70-77

    Abstract

    With the increasing availability of integrated PET/MR scanners, the utility and need for MR contrast agents for combined scans is questioned. The purpose of our study was to evaluate whether administration of gadolinium chelates is necessary for evaluation of pediatric tumors on (18)F-FDG PET/MR images.First, in 119 pediatric patients with primary and secondary tumors, we used 14 diagnostic criteria to compare the accuracy of several MR sequences: unenhanced T2-weighted fast spin-echo imaging; unenhanced diffusion-weighted imaging; and-before and after gadolinium chelate contrast enhancement-T1-weighted 3-dimensional spoiled gradient echo LAVA (liver acquisition with volume acquisition) imaging. Next, in a subset of 36 patients who had undergone (18)F-FDG PET within 3 wk of MRI, we fused the PET images with the unenhanced T2-weighted MR images (unenhanced (18)F-FDG PET/MRI) and the enhanced T1-weighted MR images (enhanced (18)F-FDG PET/MRI). Using the McNemar test, we compared the accuracy of the two types of fused images using the 14 diagnostic criteria. We also evaluated the concordance between (18)F-FDG avidity and gadolinium chelate enhancement. The standard of reference was histopathologic results, surgical notes, and follow-up imaging.There was no significant difference in diagnostic accuracy between the unenhanced and enhanced MR images. Accordingly, there was no significant difference in diagnostic accuracy between the unenhanced and enhanced (18)F-FDG PET/MR images. (18)F-FDG avidity and gadolinium chelate enhancement were concordant in 30 of the 36 patients and 106 of their 123 tumors.Gadolinium chelate administration is not necessary for accurate diagnostic characterization of most solid pediatric malignancies on (18)F-FDG PET/MR images, with the possible exception of focal liver lesions.

    View details for DOI 10.2967/jnumed.115.161646

    View details for Web of Science ID 000367862700014

    View details for PubMedCentralID PMC4703553

  • Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. The Journal of allergy and clinical immunology Philbin, V. J., Dowling, D. J., Gallington, L. C., Cortés, G., Tan, Z., Suter, E. E., Chi, K. W., Shuckett, A., Stoler-Barak, L., Tomai, M., Miller, R. L., Mansfield, K., Levy, O. 2012; 130 (1): 195–204.e9

    Abstract

    Newborns have frequent infections and manifest impaired vaccine responses, motivating a search for neonatal vaccine adjuvants. Alum is a neonatal adjuvant but might confer a T(H)2 bias. Toll-like receptor (TLR) agonists are candidate adjuvants, but human neonatal cord blood monocytes demonstrate impaired T(H)1-polarizing responses to many TLR agonists caused by plasma adenosine acting through cyclic AMP. TLR8 agonists, including imidazoquinolines (IMQs), such as the small synthetic 3M-002, induce adult-level TNF from neonatal monocytes, but the scope and mechanisms of IMQ-induced activation of neonatal monocytes and monocyte-derived dendritic cells (MoDCs) have not been reported.We sought to characterize IMQ-induced activation of neonatal monocytes and MoDCs.Neonatal cord and adult peripheral blood monocytes and MoDCs were cultured in autologous plasma; levels of alum- and TLR agonist-induced cytokines and costimulatory molecules were measured. TLR8 and inflammasome function were assayed by using small interfering RNA and Western blotting/caspase-1 inhibitory peptide, respectively. The ontogeny of TLR8 agonist-induced cytokine responses was defined in rhesus macaque whole blood ex vivo.IMQs were more potent and effective than alum at inducing TNF and IL-1β from monocytes. 3M-002 induced robust TLR pathway transcriptome activation and T(H)1-polarizing cytokine production in neonatal and adult monocytes and MoDCs, signaling through TLR8 in an adenosine/cyclic AMP-refractory manner. Newborn MoDCs displayed impaired LPS/ATP-induced caspase-1-mediated IL-1β production but robust 3M-002-induced caspase-1-mediated inflammasome activation independent of exogenous ATP. TLR8 IMQs induced robust TNF and IL-1β in whole blood of rhesus macaques at birth and infancy.IMQ TLR8 agonists engage adenosine-refractory TLR8 and inflammasome pathways to induce robust monocyte and MoDC activation and represent promising neonatal adjuvants.

    View details for DOI 10.1016/j.jaci.2012.02.042

    View details for PubMedID 22521247

    View details for PubMedCentralID PMC3387351

  • Design for Medicine- Creating Global Solutions: How Good Design Can Save the World Journal of SF Medical Society Chi, K., Stivers, C. 2012; 85 (1): 21-23